| Literature DB >> 31726671 |
Katri Eskelin1, Minna M Poranen1, Hanna M Oksanen1.
Abstract
Asymmetrical flow field-flow fractionation (AF4) separates sample components based on their sizes in the absence of a stationary phase. It is well suited for high molecular weight samples such as virus-sized particles. The AF4 experiment can potentially separate molecules within a broad size range (~103-109 Da; particle diameter from 2 nm to 0.5-1 μm). When coupled to light scattering detectors, it enables rapid assays on the size, size distribution, degradation, and aggregation of the studied particle populations. Thus, it can be used to study the quality of purified viruses and virus-like particles. In addition to being an advanced analytical characterization technique, AF4 can be used in a semi-preparative mode. Here, we summarize and provide examples on the steps that need optimization for obtaining good separation with the focus on virus-sized particles.Entities:
Keywords: field-flow fractionation; light scattering; macromolecular complex; size-based separation; virus; virus purification; virus-like particle
Year: 2019 PMID: 31726671 PMCID: PMC6921026 DOI: 10.3390/microorganisms7110555
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1(a) Principle of asymmetrical flow field-flow fractionation (AF4). Cross flow forces the sample components towards the accumulation wall, which consists of an ultrafiltration membrane layered on top of a permeable ceramic frit through which the cross-flow is pumped out. Sample components diffuse against the cross-flow force depending on their diffusion coefficients that are size-dependent. Channel flow that moves through the channel has the highest velocity in the middle of the channel. It transports sample components towards the detectors. Small sample components reach the highest velocities and elute first. In practice, the sample components occupy ~1% of the total channel thickness (w) and the rest of the flow is sample free. Virus particles are not drawn to scale. (b) Channel shape, length (L), maximum breadth (bmax), and nominal thickness (w, see a) are determined by the spacer. Due to the spacer design, the breadth of the channel decreases linearly towards the outlet end of the channel. Commercial spacers for standard analytical (top) and semi-preparative (bottom) AF4 channels from Postnova are shown.
Figure 2Retention time (tr) depends on the diffusion co-efficient of the analyzed sample, which correlates with the hydrodynamic diameter (dH). Several parameters affect retention time and have inter-dependent effects. In general, cross flow (Vc) has the strongest impact on separation. Void time (t0) and void volume (V0) are dependent on the channel thickness (w), whereas diffusion and eluent viscosity are temperature-dependent. In addition, the eluent, channel geometry, and the channel-flow rate affect retention time.
Advantages and challenges of AF4 in virus and virus-like particle (VLP) applications.
| Advantages | Challenges |
|---|---|
|
Gentle non-invasive technique. Automation in injection and fraction collection. Adjustable mobile phase composition. Size-based separation. Short analysis time. Typically high recovery yields. High repeatability between injections. Wide size range for separation in a single AF4 experiment. Easy coupling to various in-line detectors (UV, MALS, DLS, fluorescence). Easy fraction collection for off-line analysis. Various membrane materials available with different MWCO. Membrane-selective AF4 to remove components that are smaller than the membrane MWCO. Up to ~50 injections can be analysed with a single membrane. Slot flow pump option to remove the sample-free eluent. Semi-preparative and mini channels to preparative applications and analysis of scarce samples. Sample pre-processing not required. Relatively cheap running costs. |
Tedious optimization. Inter-dependent effects of experimental parameters on retention behaviour. Not routinely available. Potential mixing of normal and steric elution modes if the analyzed sample has high polydispersity in the size range. Potential membrane interactions with sample components. Sample-sample interactions if high sample loads or high cross-flow rate is applied. Lot-to-lot variation in membranes and between manufacturers. Sample dilution during fractionation. Small sample loads in standard analytical AF4. High initial investment costs. Expensive detectors. |
Figure 3Effects of instrumental parameters on AF4 separation of enveloped bacteriophage ϕ6. (a) Thinner spacer advances elution (spacers of 250 and 350 µm in orange and blue, respectively). (b) Adsorption of sample components on membrane surface causes membrane fouling (membrane aging) that influences retention time. (c) The ionic strength of the eluent affects retention time via its influence on the electrostatic interactions between the sample components, and the sample components and the membrane. (d) Decreased channel temperature slows down diffusion and retards elution. Cross-flow gradients are shown with black dashed lines (right y-axis). Transition from focusing to elution is indicated with an arrow. UV detector response is given in volts (V) (left y-axis). Eluent was 20 mM potassium phosphate buffer (pH 7.2), 1 mM MgCl2. NaCl concentration of eluent (if present), channel flow rate (Vout), void peak (V0), injected virus amounts (PFU), and membrane MWCO are indicated in the corresponding panels. A spacer with a 250 μm nominal thickness was used in b–d. The AF4 instrument used was from Postnova and its operation is described in [32]. ϕ6 was pre-purified with polyethylene glycol precipitation and two subsequent ultracentrifugations [34], Appendix A.
Figure 4AF4 separation of different-sized spherical bacteriophages. Baseline separation is obtained for ϕX174 (ø ~25 nm; grey line) and PRD1 (ø ~63 nm; blue line) or ϕ6 (ø ~71 nm; orange line) when analyzed separately. However, PRD1 and ϕ6 with similar sizes cannot be separated (peak at ~20 min) when the fractionation is performed for the mixture of ϕX174, PRD1, and ϕ6 (yellow line). The cross-flow gradient is shown with black dashed line (right y-axis). Transition from focusing to elution is indicated with an arrow. UV detector response is given in volts (V) (left y-axis). A spacer with 250 μm nominal thickness was used. Eluent was 20 mM Tris-HCl (pH 7.5), 25 mM NaCl. Injected virus amounts were: ϕX174 ~1 × 1010 PFU; PRD1 ~1 × 1011 PFU; and ϕ6 ~1 × 1011 PFU. An RC membrane with MWCO of 10 kDa and a channel flow rate of 0.3 mL/min was used. V0 is the void peak. The AF4 instrument used and its operation is described in [32]. Production and purification of viruses is summarized in Appendix A.
Figure 5The AF4 experiment is divided into the focusing and elution steps. The pre-stained protein sample was fractionated to visualize (a) the focusing site (indicated with a white arrow) and (b) the beginning of elution. (a) During focusing, sample components concentrate into a thin band (here visible as a blue zone). Focusing is achieved by applying a focusing flow (long black arrow upwards) from an opposite direction in relation to the incoming tip flow that equals to injection flow during the focusing step (short black arrow downwards). (b) Switching off the focusing flow (long grey arrow upwards) initiates elution and sample components start moving towards the outlet end of the channel (here downwards), the detectors, and the fraction collector according to their sizes. During elution, the tip flow rate is equal to the sum of channel-flow and cross-flow rates. Ports for the inlet (tip flow in, blue arrow head) and cross flow (green arrow head) in the Postnova analytical channel are indicated.
Figure 6Effect of flow rates on separation and retention time. (a) Focusing position (zfoc) affects retention time. The closer it is to the inlet, the longer is the effective channel length for the separation. Additionally, the retention times increase. (b) An increased cross-flow rate (Vc) promotes equilibration of sample components into a narrower zone closer to the accumulation wall and retards elution. (c) Increased channel-flow rate (Vout) promotes elution and shortens the required analysis time, but may induce dilution. (d) Retention time is unaffected if the ratio of cross-flow and channel-flow rate (Vc/Vout) is kept constant, whereas resolution and peak intensities can change. Here, increased flow rates induce virus aggregation, observed as an increase in the intensity of the peak eluting at the end of the cross-flow gradient. UV detector response is given in volts (V) (left y-axis). Cross-flow gradients are shown with dashed lines (right y-axis). Transition from focusing to elution is indicated with an arrow. Injection (Vinj), cross-flow (Vc), and channel-flow (Vout) rates are indicated in the figures. V0 is the void peak. Spacer with 250 μm nominal thickness was used. Eluent was 20 mM Tris-HCl (pH 7.5), 25 mM NaCl. Injected ϕ6 amount was ~7 × 1010 PFU corresponding to ~15 μg [34], see Appendix A.
Summary of AF4 studies on VLPs and the AF4 operation conditions used.
| Virus 1) | Specimen | Analysis/Study | Membrane 3) | MWCO, kDa | Spacer, μm | Channel 4) | VC Gradient 5) | VC, Start | VC, End | VOUT | Total Analysis Time 6) (min) | Eluent | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EV71, CVA16 | VLPs (Ø ~30 nm) | Quality2), yield | RC | 10 | 350 | S | C | 1.0 | 0 | 1.2 | 50 (6 + 30) | 50 mM Tris-glycine (pH 7.4), 150 mM NaCl | [ |
| HBV (HBsAg) | VLPs (Ø ~23–29 nm) | Quality, salt induced aggregation, stability | RC | 10 | 350 | S | C+L | 1.0 | 1.0 | 1.0 | 55 (5 + 40 + 5 + 5) | 20 mM phosphate buffer (pH 7.4) | [ |
| MPV | VLPs (VP1) (Ø ~40–60 nm) | VLP characterization: in vitro and in vivo assembled, VC optimization, sample load | RC | 10 | 350 | S | C+L | 0.75 | 0 | 0.75 | ~60 (10 + 30) | 10 mM Tris-HCl (pH 8.0), 50 mM NaCl, 10 mM CaCl2 or 20 mM Tris-HCl (pH 7.4), 200 mM NaCl, 1 mM CaCl2, 5% (v/v) glycerol | [ |
| MPV | Disassembled VLPs, pentamers | Quality | As in [ | 40 mM Tris-HCl (pH 8.0), 200 mM NaCl, 1 mM EDTA, 5 % (v/v) glycerol, 5 mM DTT | [ | ||||||||
| MPV | VLPs | Size and size distribution: effect of affinity tags on VP17) and VP2, effect of packaged DNA or VP2. Method validation8) | As in [ | 10 mM Tris (pH 8.0), 50 mM NaCl, 0.01 mM CaCl2 | [ | ||||||||
| MPV | In vitro assembled VLPs (VP1) | Quality | As in [ | 40 mM Tris (pH 7.2 or 8.0), 200 mM NaCl, 5% (v/v) glycerol, 0.05 or 0.2 mM CaCl2 | [ | ||||||||
| MPV | VLPs | VLP formulation, stability, aggregation, effect of affinity tags (VP1) | As in [ | PBS (pH 7.4)9) | [ | ||||||||
| MPV | In vitro assembled VLPs, VP1 capsomers (wild type and modified) | Formulation of efficient in vitro assembly reaction, VLP quality, recovery | As in [ | PBS (pH 7.4) | [ | ||||||||
| JCV | VLPs (Ø ~40 nm) and VP1 pentamers | VLP quality, optimal production, effect of packaged DNA, dissociation | RC | 10 | 350 | S | C+L | 0.75, 1.0, 1.5 | 0 | 0.75 or 1.0 | 50 (10 + 20–35 + 1–5) | VLPs: 20 mM Tris-HCl (pH 7.5), 50/150 mM NaCl. VP1 Pentamers: 280 mM NaCl, 1 mM EGTA, 5 mM DTT | [ |
| JCV | VLPs | VLP quality, optimal production conditions | RC | 10 | 440 | S | L | 1.5 | 0 | 0.5 | 50 (10 + 25) | 20 mM Tris-HCl (pH 7.5), 150 mM NaCl | [ |
| Qβ, NicQβ | VLPs | Optimization (membranes, flow rates, focusing time). VLP (3.5 MDa) quality & stability. Method validation8) | RC (PES, CA) | 10 | 350 | S | C+L+L | 2.0 | 0.15, 0 | 1.5 | 56 (8 + 18 + 15 + 5) | 20 mM Na phosphate buffer (pH 7.0), 150 mM NaCl | [ |
| Qβ | VLPs | VLP quality | RC | 10 | 350 | M | C+L | 1.0 | 0 | 1.2 | 31 (6+14+5) | As above | [ |
1) Virus abbreviations: EV71, enterovirus 71; CVA16, coxsackie virus A16; HBsAg, hepatitis B surface antigen; JCV, human polyoma JC virus; MPV, murine polyoma virus, NicQb, VLPs of bacteriophage Qβ that wears covalently linked nicotine haptens. 2) Quality: Molar mass, size, size distribution, heterogeneity, presence of aggregates, oligomers, degradation products. 3) RC, regenerated cellulose; CA, cellulose acetate; PES, polyether sulfone. 4) Channel type: S, standard analytical channel (length ~26 cm); M, mini channel (length ~18 cm). 5) Cross-flow gradient types: C, constant cross-flow rate; L, linear cross-flow gradient. Typical elution programs also utilize rinse periods without applied cross flow at the end of the run (not indicated in the table). 6) Total analysis time is dependent on the time that the analysis is continued after the cross flow has ceased to 0 mL/min. In many of the publications this is not clearly indicated. Focusing and injection time and the length of elution gradient are given in parenthesis. 7) VP, viral protein 8) Method validation: AF4-MALS compared to electrospray differential mobility analysis and transmission electron microscopy (MPV) or size exclusion chromatography and dynamic light scattering (Qβ). 9) PBS, phosphate buffered saline (pH 7.4).
Summary of AF4 studies on viruses and used operation conditions for standard analytical channel.
| Virus 1), Diameter, nm 2) | Specimen | Analysis/Study 3) | Membrane 3) | MWCO, kDa (kDa) | Spacer, μm | VC Gradient 4) | VC, Start | VC, End | VOUT | Total Analysis Time 5) (min) | Eluent | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Influenza(~113) | Crude and purified viruses | AF4 method optimization. Polydispersity, effect of purification and excipient addition, virus particle counts. Method validation 6) | RC | 10 | 350 | L | 0.4 or 0.6 | 0 | 0.8–1.0 | ~50–75 (15 + 35–60) | 0.1 M K-phosphate (pH 7.4) | [ |
| Influenza, AdV | Purified viruses | Aggregation and virus concentration | RC, CA | 10 | 350 | L | n.d.* | n.d. | 1.0 | ~25–35 | Influenza aqueous, AdV 10% (v/v) glycerol | [ |
| Influenza | Purified viruses, culture supernatants | Quantitation and sensitivity, size distribution | PES | 10 | 350 | L | 0.3 | 0 | 1.0 | ~60 (35) | 0.01 M Na-/K-phosphate (pH 7.4), 0.14 M NaCl | [ |
| T4, MS2, Y1, C2 (~25–110) | Purified viruses | Effect of viruses on optical backscattering in oceans: refractive index calculations | RC | 10 | n.d. | C | 0.92 | 0.92 | 1.9 | n.d. | PBS (pH 7.2) or boric acid-buffered saline (pH 9.5), 0.1 % (v/v) Pluronic F68 | [ |
| PRD1(~63) | Culture supernatants, PEG-precipitate, purified viruses | Virus purification: AF4 method optimization, sample load, quality, progress of infection | RC | 100 | 350, 250 | L, L+E | 1.0 | 0.1 | 0.2, 0.5 | ~60(5–15 + 25–45) | 20 mM K-phosphate (pH 7.2), 1 mM MgCl2 | [ |
| His1, HRPV1, HVTV-1, HCIV-1 (~40–100) | Culture supernatants, PEG-precipitate, purified viruses | Virus purification: yield, quality 7), progress of infection (His1) | RC | 100, 10 | 350, 250 | L, L+E | 1.0 | 0.1 | 0.2, 0.5 | ~60 (5–15 + 25–45) | 20–50 mM Tris-HCl (pH 7.2–7.5), 0.5–1.5 M NaCl, 35–100 mM MgCl2, 1–2 mM CaCl2, ± 10–28 mM KCl, ±47 mM MgSO4 | [ |
| ϕ6(~71) | Culture supernatants, PEG-precipitate, purified viruses | Virus purification: yield, quality | RC | 100, 10 | 350, 250 | L, L+E | 1.0 | 0.1 | 0.2, 0.5 | ~60 (5–15 + 25–45) | 20 mM K-phosphate (pH 7.2), 1 mM MgCl2 | [ |
| ϕ6 | Purified viruses | Virus disassembly, purification of functional subassemblies | RC | 10 | 250 | C+L | 1.0 | 0.1 | 0.2 | ~50 (5–10 + 5+25) | 10 mM K-phosphate (pH 7.2), 1 mM MgCl2, ±0.1 mM CaCl2, ±150 mM NaCl, ±20 mM EGTA | [ |
* N.d. not determined. 1) Virus name abbreviations: AdV, adenovirus; HVTV-1, Haloarcula vallismortis tailed virus 1; HRPV-1, Halorubrum pleomorphic virus 1; HCIV-1, Haloarcula californiae icosahedral virus 1; T4, MS2, Y1, C2, PRD1, ϕ6 are bacteriophages. 2) Dgeo = geometric diameter calculated from AF4-MALS derived root mean square radius assuming homogenous or hard spheres or obtained from transmission electron microscopy. For tailed phages, the diameter refers to the capsid (head) size. For pleomorphic viruses the size range of the smallest and largest dimension is given. 3) RC, regenerated cellulose; CA, cellulose acetate; PES, polyether sulfone. 4) Cross-flow gradient type: C, constant cross flow; L, linear cross-flow gradient; E, exponential cross-flow gradient. Typically, elution ends with a rinsing period without applied cross flow. Rinse periods are not indicated in the column. 5) Total analysis time is dependent on the time that the analysis is continued after the cross flow has ceased to 0 mL/min. In many of the publications this is not clearly indicated. Focusing and injection time and the length of elution gradient is given in parenthesis. 6) Method validation: Comparison of AF4-MALS to size-exclusion chromatography coupled to MALS; transmission electron microscopy; atomic force microscopy: median tissue culture dose; fluorescent focus assay; reverse transcription polymerase chain reaction. 7) Quality= molar mass, size, size distribution, purity, heterogeneity, aggregation, and number of infectious viruses.
Summary of virus purification.
| ϕ6 | PRD1 | ϕX174 | |
|---|---|---|---|
| Buffer | 10 mM K phosphate (pH 7.2), 1 mM MgCl2 | 10 mM K phosphate (pH 7.2), 1 mM MgCl2 | 50 mM Tris-HCl (pH 7.2), 100 mM NaCl |
| Lysate clearance | ~10,000× | ~10,000× | ~15,000× |
| PEG precipitation | 10% (w/v) PEG, 0.5 M NaCl | 10% (w/v) PEG, 0.5 M NaCl | 10% (w/v) PEG, 0.5 M NaCl |
| Collection of PEG precipitate | ~10,000× | ~10,000× | ~15,000× |
| Rate zonal centrifugation | 5–20% (w/v) 1, 103,864× g, 50 min, 15 ºC | 5–20% (w/v) 1, 103,864×g, 55 min, 15 ºC | 5–20% (w/v) 1, 103,864×g, 75 min, 15 ºC |
| Differential centrifugation | 113,580× | 113,580× | 144,406× |
| Given g-values are the max values. | |||
1) linear sucrose gradient